The role of frontal EEG in predicting clinical response of major depressive disorder to intranasal ketamine and esketamine.
Journal of Affective Disorders November 22, 2025 Carlos Trenado, Erich Seifritz, Sebastian Olbrich et al. 4 citations
Ketamine and its enantiomer esketamine are NMDA receptor antagonists that have shown consistent antidepressant effects in major depression disorder (MDD). These effects suggest an active role of glutamate in the pathophysiology of depression. It has been hypothesized that acute increase of glutamate neurotransmission in the prefrontal cortex following treatment with (es)ketamine leads to...